CD274 and non-small cell lung carcinoma: In the CodeBreak 100 trial, 89.8% (53/59) of previously treated NSCLC patients with mKRAS G12C received anti-PD-1/PD-L1 therapy along with sotorasib and demonstrated an ORR of 32.2%, and a median PFS of 6.3 months [52].